BlackRock Inc. boosted its stake in shares of Amedisys Inc (NASDAQ:AMED) by 2,877.7% during the first quarter, Holdings Channel reports. The institutional investor owned 5,676,870 shares of the health services provider’s stock after buying an additional 5,486,225 shares during the period. BlackRock Inc.’s holdings in Amedisys were worth $290,032,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Sivik Global Healthcare LLC increased its stake in Amedisys by 60.9% in the first quarter. Sivik Global Healthcare LLC now owns 34,607 shares of the health services provider’s stock valued at $1,768,000 after buying an additional 13,097 shares in the last quarter. State Street Corp increased its stake in Amedisys by 4.0% in the fourth quarter. State Street Corp now owns 691,263 shares of the health services provider’s stock valued at $29,472,000 after buying an additional 26,377 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Amedisys during the fourth quarter valued at about $870,000. OppenheimerFunds Inc. increased its stake in Amedisys by 3.5% in the first quarter. OppenheimerFunds Inc. now owns 446,147 shares of the health services provider’s stock valued at $22,794,000 after buying an additional 15,289 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in Amedisys by 8,881.4% in the first quarter. Bank of Montreal Can now owns 34,848 shares of the health services provider’s stock valued at $1,780,000 after buying an additional 34,460 shares in the last quarter. Hedge funds and other institutional investors own 97.66% of the company’s stock.
Shares of Amedisys Inc (NASDAQ AMED) opened at 61.35 on Monday. The firm’s 50-day moving average price is $61.38 and its 200 day moving average price is $51.88. The stock has a market cap of $2.07 billion, a P/E ratio of 45.44 and a beta of 0.94. Amedisys Inc has a one year low of $34.58 and a one year high of $65.91.
Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, May 2nd. The health services provider reported $0.47 EPS for the quarter, beating the consensus estimate of $0.41 by $0.06. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. The company had revenue of $370.46 million for the quarter, compared to analyst estimates of $370.03 million. During the same period last year, the company posted $0.33 earnings per share. Equities research analysts expect that Amedisys Inc will post $2.07 EPS for the current fiscal year.
Several equities research analysts recently issued reports on AMED shares. Jefferies Group LLC reiterated a “buy” rating and issued a $57.00 price objective on shares of Amedisys in a report on Friday, April 28th. Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective on the stock in a report on Wednesday, May 3rd. Zacks Investment Research downgraded Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Royal Bank of Canada reiterated a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a report on Monday, June 5th. Finally, Stephens upped their price target on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a report on Thursday, May 4th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $58.38.
In other news, insider Lawrence R. Pernosky sold 11,500 shares of Amedisys stock in a transaction dated Wednesday, May 10th. The stock was sold at an average price of $58.97, for a total transaction of $678,155.00. Following the sale, the insider now directly owns 30,093 shares of the company’s stock, valued at $1,774,584.21. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Scott G. Ginn sold 23,828 shares of Amedisys stock in a transaction dated Monday, May 8th. The stock was sold at an average price of $58.62, for a total value of $1,396,797.36. Following the sale, the insider now directly owns 13,018 shares in the company, valued at $763,115.16. The disclosure for this sale can be found here. Insiders sold 56,828 shares of company stock worth $3,350,922 over the last three months. 2.80% of the stock is currently owned by corporate insiders.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284791/blackrock-inc-boosts-position-in-amedisys-inc-amed.html
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.